Xenon Pharmaceuticals (NASDAQ:XENE) Shares Up 7.8% – Here’s Why

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) shares shot up 7.8% on Wednesday . The company traded as high as $67.16 and last traded at $68.2840. 1,630,621 shares changed hands during trading, an increase of 20% from the average daily volume of 1,355,927 shares. The stock had previously closed at $63.37.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. HC Wainwright upped their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday. Wedbush dropped their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research note on Monday, March 16th. JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “overweight” rating in a report on Wednesday, May 27th. Finally, Needham & Company LLC lowered their target price on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $77.20.

Xenon Pharmaceuticals Stock Up 9.4%

The stock has a market capitalization of $6.70 billion, a P/E ratio of -14.63 and a beta of 0.61. The stock’s 50 day moving average price is $55.28 and its 200-day moving average price is $50.58.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the business posted ($0.83) EPS. Analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Insider Buying and Selling at Xenon Pharmaceuticals

In related news, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at $77,318.70. This represents a 44.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the sale, the director directly owned 24,896 shares in the company, valued at approximately $1,322,973.44. The trade was a 5.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.07% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its position in Xenon Pharmaceuticals by 11.3% during the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after acquiring an additional 142,452 shares during the last quarter. HighVista Strategies LLC increased its position in shares of Xenon Pharmaceuticals by 80.2% during the third quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock worth $3,300,000 after purchasing an additional 36,570 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth $5,342,000. Peregrine Capital Management LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $7,837,000. Finally, Jain Global LLC purchased a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $10,133,000. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.